

May 11, 2023

BSE Limited

Department of Corporate Services Listing Department, PJ Tower, Dalal Street, Mumbai 400001, India Scrip Code: **524816** Natco Pharma Limited Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

> National Stock Exchange of India Ltd Listing Department, 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai 400051, India Scrip Code: NATCOPHARM

Sir/Madam,

Sub: Buy Back of fully paid-up equity shares of face value of Rs.2/- each (the "Equity Shares") of Natco Pharma Limited (the "Company") under the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 as amended (the "Buyback Regulations")

With reference to the captioned subject matter, the Company hereby submits the daily report pursuant to regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought-back on May 11, 2023:

Name of the Broker	Number of Equity Shares Bought Back on (May 11, 2023)		Total shares bought back on May 11,	Average Price of Acquisition (Rs.)*
	BSE	NSE	2023	
DAM Capital Advisors Limited	Nil	6,06,071	6,06,071	641.8102*
Total (A)	Nil	6,06,071	6,06,071	641.8102*
Cumulative Equity Shares bought as on Yesterday (B)				28,38,929
Less: Quantity Closed Out Today (C)				Nil
Quantity Closed Out as on Yesterday (D)				Nil
Total Quantity closed out (C+D=E)				Nil
Total Equity Shares bought back as on May 11, 2023 (A) +(B) - (E)				34,45,000

Notes:

- 1) *Excludes Transaction Costs and brokerage charges
- 2) Previous reporting period is the day before the current reporting date when the Company has last filed report on Equity Shares bought back - May 10, 2023
- 3) Current reporting period is the day on which this report is being filed with the stock exchanges, being May 11, 2023.
- 4) The above information is subject to settlement as per the existing rules for secondary market transactions of the Stock Exchanges and verification of Equity Shares bought back, where applicable.

The details will also be made available on the website of the Company under following link: <u>https://www.natcopharma.co.in/investors/shareholder-information/buyback/</u>

For Natco Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer